Antimicrobial Stewardship

Fedora Pharmaceuticals is presenting new preclinical data at the IMARI conference demonstrating that its lead candidate, FPI-2119, shows strong activity against some of the most dangerous drug-resistant Gram-negative infections, supporting its advancement toward clinical trials.

This past December, the FDA approved both zoliflodacin and gepotidacin for this sexually transmitted infection marking a significant advance amid rising antibiotic resistance. Here is an overview of the antibiotics.

This week, read about the CDC's analysis on the continuing burden of COVID-19 on a certain population, watch an Emory nurse provide an overview of donning and doffing personal protective equipment when caring for patients with high-consequence infectious disease, a review of diagnostics and treatments for invasive candidiasis, and more.

The partnership is a global collaboration to develop Debio1453, a first-in-class antibiotic targeting multidrug-resistant gonorrhea, aiming to strengthen the fragile antibiotic pipeline and ensure future treatment options.

This week, read articles from our recent issue on topics including invasive fungal disease in transplantation, lenacapavir's role in PrEP, antimicrobial treatment around non–carbapenemase-producing carbapenem-resistant enterobacterales, and more.

Here is a case study of a patient with injection drug use, a patent foramen ovale, and recurrent MRSA bacteremia who developed rare, fatal quadruple-valve infective endocarditis involving all 4 heart valves, highlighting the high mortality risk and importance of early recognition, surgical consultation, and substance use treatment.

We are launching our new monthly column looking at federal regulatory topics including recent decisions. In this column, we look at the FDA approvals of 2 antibiotics last month.

How stewardship teams communicate determines whether interventions feel like policing or collaboration. Using structured, data-driven frameworks— advocacy-inquiry-listen-teach and DART—creates psychological safety to explore understanding and supports shared decision-making.

Non–carbapenemase-producing carbapenem-resistant Enterobacterales (CRE) isolates are the most common mechanism of CRE in the United States, but the optimal antimicrobial treatment remains to be elucidated.

Here are some therapeutics and a vaccine that will be reporting data, starting a trial, or filing their data to regulatory agencies in order to seek approval this year.

This week, listen in on commentary around the changes to the childhood vaccine schedule, read SIDP's column on the next-generation antifungals as well as combination therapeutics for Candida auris, and the Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing breakpoint recommendations.

The subcommittee approved the removal of doxycycline and tetracycline breakpoints, revised aminoglycoside breakpoints for Acinetobacter spp, and added aztreonam-avibactam breakpoints for Enterobacterales.

Findings from a recent study challenge the need for high-dose trimethoprim-sulfamethoxazole in managing Stenotrophomonas maltophilia pneumonia, finding lower doses may offer comparable efficacy.

A recent study examined how rurality and the availability of postdischarge follow-up influence clinicians’ decisions on antibiotic duration at discharge for patients hospitalized with community-acquired pneumonia.

This week, read about increasing influenza activity, an approach to de-escalating empiric broad spectrum antibiotics for clinically stable patients with community-onset sepsis, and more Emory Healthcare Media Day interviews around PPE and treating high-consequence infectious disease.

Shortening course of empiric broad spectrum antibiotics for community-onset sepsis was associated with fewer days of antibiotics and hospitalization and no increase in mortality.

This week, check out our Media Day coverage from Emory, the WHO report on malaria, and more.

This week, learn more about Emory's approach around treating high-consequence infectious diseases such as Ebola, a UNC researcher's work in sequencing syphilis genomes in the search to develop a global vaccine, how the US is in danger of losing its elimination status for measles, and more.

With a novel, non–cross-resistant mechanism and phase 3 data showing noninferior efficacy to injectable standard therapy, zoliflodacin could become a novel treatment that expands clinician choice and strengthens global efforts to combat antimicrobial-resistant gonorrhea. Innoviva CMO David Altarac, MD, offers further insights about the newly-approved antibiotic and its potential place in the market.

This week, check out our coverage on 2 antibiotic FDA approvals, and clinicians weigh in on the ACIP recommendations on the hepatitis B virus (HBV) vaccine.

The antibiotic's approval was based from phase 3 results demonstrating noninferiority to a combination therapy.

GSK’s David Payne, PhD, provides more information are the data from the EAGLE-1 trial.

The federal nod was given based from the phase 3 data of the EAGLE-1 trial, which showed noninferiority to combination therapy. This approval provides a new oral option.

The federal agency approved Augmentin XR in just 2 months through the new CNPV pilot program, marking a potential step toward rebuilding domestic antibiotic manufacturing and addressing drug shortages.

Population study corroborates 2019 FDA alert based on case reports of acute respiratory failure with TMP-SMX in healthy adolescents and young adults.